Biovica initiates a collaboration with Mayo Clinic to study DiviTum[®] for the on-treatment monitoring of metastatic breast cancer patients receiving CDK 4/6 inhibitors
Biovica and Mayo Clinic have entered into an agreement to study the clinical benefit of using DiviTum[®] as a blood-based test, monitoring the tumor response to therapy in patients with metastatic breast cancer.The main purpose of including DiviTum[®] in studies performed at Mayo Clinic is to evaluate the changes in serum thymidine kinase activity, measured by DiviTum[®], in patients with hormone positive metastatic breast cancer treated with today’s standard regimens – including CDK 4/6 inhibitors. DiviTum[® ]measurements at the start of therapy and during treatment will be correlated to